Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:34 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies
NCT03205046 · Acerta Pharma BV · PHASE1/PHASE2 · terminated · last registry update 2021-01-06 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor's decision not to pursue further development of the combination in DLBCL” | – | Registry record, Acerta Pharma BV |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against BTK within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-10-29Phase 3 first posted: BeOne Medicines, Zanubrutinib + Rituximab (NCT05100862)
- 2021-09-27Phase 3 first posted: AstraZeneca, Acalabrutinib + Venetoclax (NCT05057494)
- 2021-09-21Phase 3 first posted: Beijing InnoCare Pharma Tech Co., Ltd., Orelabrutinib and R-CHOP + R-CHOP (NCT05051891)
- 2021-08-27Phase 3 first posted: Loxo Oncology, Inc., Pirtobrutinib + Bendamustine (NCT05023980)
- 2021-08-18Results posted on the registry: Acerta Pharma BV, Acalabrutinib (Arm A) + Acalabrutinib (Arm B) (NCT02337829)
- 2021-07-16Phase 3 first posted: Loxo Oncology, Inc., Pirtobrutinib + Venetoclax (NCT04965493)
- 2021-02-02Results posted on the registry: Washington University School of Medicine, Bendamustine + Rituximab (NCT03623373)
- 2020-12-14Phase 3 first posted: Loxo Oncology, Inc., Pirtobrutinib + Idelalisib (NCT04666038)
- 2020-12-10Phase 3 first posted: Loxo Oncology, Inc., Pirtobrutinib + Ibrutinib (NCT04662255)
- 2020-10-29Phase 3 first posted: German CLL Study Group, Ibrutinib + Venetoclax (NCT04608318)
- 2020-10-14Phase 3 first posted: Hoffmann-La Roche, Fenebrutinib + Teriflunomide (NCT04586010)
- 2020-10-14Phase 3 first posted: Hoffmann-La Roche, Fenebrutinib + Teriflunomide (NCT04586023)
- 2020-10-08Results posted on the registry: National Heart, Lung, and Blood Institute (NHLBI), Ibrutinib + Fludarabine (NCT02514083)
- 2020-09-24Phase 3 first posted: Principia Biopharma, a Sanofi Company, Rilzabrutinib + Placebo (NCT04562766)
- 2020-09-10Phase 3 first posted: Hoffmann-La Roche, Fenebrutinib + Ocrelizumab (NCT04544449)
- 2020-08-28Phase 3 first posted: Acerta Pharma BV, acalabrutinib + placebo (NCT04529772)
- 2020-07-29Results posted on the registry: Acerta Pharma BV, ACP-196 (NCT02586857)
- 2020-05-15Results posted on the registry: Dana-Farber Cancer Institute, Ibrutinib + Fludarabine (NCT02251548)
- 2020-04-24Results posted on the registry: Acerta Pharma BV, Acalabrutinib (ACP-196) + Acalabrutinib (ACP-196) (NCT02180724)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision